Kohlberg-backed Worldwide Clinical Trials to acquire Catalyst Clinical Research from QHP Capital.

Kohlberg-backed Worldwide Clinical Trials, a mid-sized, global contract research organization providing full-service drug development solutions, agreed to acquire Catalyst Clinical Research, a global contract research organization providing specialized clinical trial solutions, from QHP Capital, a private equity firm. Financial terms were not disclosed. "Bringing Worldwide and Catalyst together elevates our capabilities in oncology and provides a new solution for our collective customers. We are excited to add Catalyst’s deep operational expertise and oncology credibility to our own well-known CNS specialist CRO capabilities to create a differentiated biotech-oriented oncology solution," Alistair Macdonald, Worldwide Clinical Trials CEO.